Asset

PEMBROLIZUMAB

Incyte Corp. Common Stock

Revenue

No revenue reported in loaded filings.

Clinical trials (1)

NCT IDPhaseStatusStartCompletionSponsor nameTitle
NCT02178722phase1_2completed2014-07-172018-11-26Incyte CorporationStudy to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

FDA applications (0)

This company has no applications containing this asset.

Marketed products (0)